In a bid to acquire the minority stake in the Mumbai-based firm for a cash consideration of Rs 10.5 crore, Goldencross Pharma, a wholly-owned subsidiary of Cipla, has signed an agreement.
Drug major CiplaNSE 0.81 % recently revealed that it has inked a pact to acquire 11.71 per cent stake in Wellthy Therapeutics.
It was revealed that as part of the agreement, the partners plan to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.
A multi-lingual clinically-validated digital disease management platform will be made available, as per the agreement, to patients living with diabetes or cardiovascular diseases via doctors’ clinics or co-packaging on select Cipla brands.
The forum brings together behavioural science, real-world clinical evidence and artificial intelligence to provide real-time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.
The transaction is expected to close before March 10.